DDInter1230 DDInter1476
Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Pirbuterol
Mirtazapine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Pirbuterol
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Gastrointestinal pain {u} (Side Effect) is caused by {v} (Compound) Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Isoprenaline {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)
Mirtazapine (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Pirbuterol (Compound)
Mirtazapine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Pirbuterol (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Mirtazapine (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Mirtazapine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Mirtazapine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Salbutamol (Compound) and Salbutamol (Compound) resembles Pirbuterol (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Mirtazapine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)